GLI2

Across TCGA pan-cancer cohorts, GLI2 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated GLI2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher GLI2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLI2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, COAD, and UCEC are the cancer types where GLI2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.226	0.765	<.001	23	view →
COAD	OS	Median	II,III,IV	0.580	0.862	<.001	13	view →
UCEC	DFS	Median	All	0.964	0.823	.005	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
SKCM	DFS	Median	All	0.750	0.600	.005	8	view →
OV	OS	Median	II,III,IV	0.577	0.845	.029	6	view →
HNSC	DFS	Median	II,III,IV	0.341	0.698	.018	6	view →
BLCA	OS	Median	III,IV	0.090	0.582	<.001	6	view →
PRAD	DFS	Median	All	0.534	0.935	<.001	6	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
SCLC	OS	Median	III,IV	1.000	0.241	.029	5	view →
READ	OS	Median	II,III,IV	0.204	0.652	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

GLI2–ACC (DFS)

Open the ACC breakdown →